(Q33371973)

English

The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Mark N Polizzotto

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Constantine S. Tam

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Alvin Milner

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

E Henry Januszewicz

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

H Miles Prince

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

David Westerman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Max M Wolf

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

John F Seymour

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

0 references

publication date

1 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

107

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

773-780

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16847886%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Changing incidence of non-Hodgkin lymphomas in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in leukemia incidence and survival in the United States (1973–1998)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukemias, myeloma, and other lymphoreticular neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic lymphocytic leukaemia at a county hospital in southern Sweden.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity considerations in geriatric oncology research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of cancer in the older person: a practical approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Antineoplastic chemotherapy of the older cancer patient

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33371973&oldid=1592048516"